Form 4: Vaxcyte SVP Mikhail Eydelman Reports Stock Transactions
SEC Form 4
Mikhail Eydelman, SVP, General Counsel & Corporate Secretary of Vaxcyte, Inc., reports acquisition and disposal of common stock and stock options.
Summary
- On February 27, 2025, Mikhail Eydelman acquired 14,484 shares of Vaxcyte common stock related to restricted stock units (RSUs) at $0.
- On the same day, Eydelman was granted a stock option to purchase 48,357 shares of common stock at an exercise price of $74.22, vesting monthly from March 27, 2025, until February 26, 2035.
- On February 28, 2025, Eydelman disposed of 470 shares of common stock at $73.02 to cover tax withholding obligations upon RSU vesting.
- On March 3, 2025, Eydelman disposed of 616 shares of common stock at $72.10 to cover tax withholding obligations upon RSU vesting.
- Following these transactions, Eydelman directly owns 41,620 shares of Vaxcyte common stock and holds options for 48,357 shares.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine filing showing stock transactions by an executive. The acquisition of shares through RSUs and option grants is mildly positive, while the disposal for tax obligations is neutral.
Positives
- The grant of stock options and RSUs to a key executive like the SVP, General Counsel & Corporate Secretary can be seen as a positive incentive for continued service and alignment with company goals.
Negatives
- The disposal of shares to cover tax obligations, while routine, slightly reduces the executive's direct holdings.
Risks
- The value of the stock options is dependent on the future performance of Vaxcyte's stock price.
- The vesting of RSUs and stock options is contingent upon the executive's continuous service with the company.
Future Outlook
The reporting person's future holdings will change as RSUs vest and stock options are exercised, contingent on continued service and market conditions.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which can be informative for investors.
Comparison to Industry Standards
- Stock option grants and RSU awards are common compensation practices in the biotechnology industry to incentivize executives.
- The vesting schedules described are typical for such awards, aligning executive compensation with long-term company performance.
- Comparing the size of the option grant to those of executives at similar-stage biotech companies (e.g., Moderna, BioNTech at similar points in their development) would provide further context.
Stakeholder Impact
- Shareholders can use this information to understand executive compensation and alignment with company performance.
- Employees may view the stock option grants as a positive sign of the company's commitment to its leadership.
Next Steps
- Continued monitoring of insider transactions through future Form 4 filings.
- Tracking the vesting and exercise of stock options and RSUs.
Key Dates
| Date | Description |
|---|---|
| 02/27/2025 | Acquisition of 14,484 shares of Common Stock underlying restricted stock units and grant of stock option for 48,357 shares. |
| 02/28/2025 | Disposal of 470 shares of Common Stock to cover tax withholding obligations. |
| 03/03/2025 | Disposal of 616 shares of Common Stock to cover tax withholding obligations. |
| 03/03/2025 | Date of Form 4 filing. |
| 03/27/2025 | First vesting date for stock options. |
| 09/07/2025 | First vesting date for 25% of the shares subject to the RSU award. |
| 02/26/2035 | Expiration date for stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.